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Correlation between preimplantation genetic
diagnosis for chromosomal aneuploidies and the
efficiency of establishing human ES cell lines
Yury Verlinsky a,1, Nicolas H. Zech a,b,⁎,1, Nikolai Strelchenko a,
Valeri Kukharenko a, Artem Shkumatov a, Zev Zlatopolsky a, Anver Kuliev aa Reproductive Genetics Institute, 2825 North Halsted, Chicago, IL 60657, USA
b Department of Obstetrics, University Hospital Zurich, Zurich, SwitzerlandReceived 19 May 2008; received in revised form 9 July 2008; accepted 14 July 2008Abstract There are several sources from which human embryonic stem cell (hESC) lines can be generated: surplus
embryos after in vitro fertilization procedures, one- and three-pronuclear zygotes, early arrested or highly fragmented
embryos that have reached the blastocyst stage, or otherwise chromosomally or genetically abnormal embryos after
preimplantation genetic diagnosis (PGD). We report on the efficiency of establishing hESC lines from blastocysts with proven
meiotic or mitotic errors after sequential testing of both polar bodies and blastomere analysis on day 3. The success rate
of establishing hESC lines originating from blastocysts carrying a meiotic error was as low as 2.4% and differed significantly
from the success rate of establishing hESC lines originating from blastocysts with balanced meiotic errors (21.6%) or mitotic
errors (after sequential testing (9.1%) and after blastomere testing alone (12.2%)). This suggests that it may be reasonable to
apply sequential PGD prior to the initiation of hESC culture. Information about the karyotype may in the future help refine the
methods and possibly improve the efficiency by which hESC lines are derived from embryos with prezygotic abnormalities.
Additionally, it may in general prove very difficult to obtain abnormal hESC lines for scientific study from aneuploid PGD
embryos, which will limit our ability to study the biological consequences of chromosomal abnormalities. Furthermore, the
success rates for generating aneuploid cell lines originating from fertilized oocytes carrying a prezygotic nondisjunction error
seem to mirror the miscarriage rates during pregnancy of embryos carrying such errors.
© 2008 Elsevier B.V. All rights reserved.Introduction
Human embryonic stem cells (hESC) are usually produced
through the use of surplus embryos derived from in vitro
fertilization procedures. In many countries, legislation
influences the availability of embryos, with some countries
even banning the creation of embryos for any other purpose⁎ Corresponding author.
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doi:10.1016/j.scr.2008.07.002than to transfer them back to the oocyte donor (Liao, 2005).
Still, the ethical aspects of using even surplus embryos to
generate hESC lines are discussed controversially (Boer,
1999; Meyer, 2000; Bahadur, 2003; Ohara, 2003; Reichhardt
et al., 2004; Devolder, 2005; Edwards, 2005; Pennings, 2006;
European Group on Ethics in Science and New Technologies,
Opinion No. 15, Ethical aspects of human stem cell research
and use: http://ec.europa.eu/european_group_ethics/
docs/avis15_en.pdf, accessed on 14 November 2000).
For example, laboratories in the United States using hESC
lines derived from surplus embryos after 9 August 2001 are
denied federal funds for research. At the same time, state.
79PGD for chromosomal aneuploidies and establishment of hESC linesand private agencies remain free to fund the acquisition of
embryos for hESC research, including the derivation of new
hESC lines. The supply of available embryos remains short of
demand, even in those countries where hESC research is
permitted. In the United States, only around 2.8% of surplus
embryos are available for research (Hoffman et al., 2003), 2%
in Canada (Baylis et al., 2003), and only 0.4% in Switzerland
(Koeferl-Puorger et al., 2006), because of the restrictive
legal regulations.
There are several other sources from which hESC lines can
be generated, for example, the use of one- and three-
pronuclear zygotes, early arrested or highly fragmented
embryos that have reached the blastocyst stage, or other-
wise abnormal embryos with gene and chromosome disorders
obtained through preimplantation genetic diagnosis (PGD)
(Verlinsky et al., 2005, 2006; Lerou et al., 2008). Human ESC
lines produced from aneuploid embryos provide an extre-
mely valuable source for research on the primary effects of
chromosomal abnormalities (Verlinsky et al., 2008).
We report on the efficiency of establishing hESC lines from
blastocysts with euploid and aneuploid karyotypes after
sequential testing of both polar bodies (PBs) and blastomere
analysis on day 3. Our findings suggest that it seems reason-
able to perform sequential polar body and blastomere testing
on embryos prior to the initiation of hESC culture for the
derivation of new lines. We argue that embryos with euploid
and aneuploid karyotypes may show significantly different
success rates for establishing hESC lines owing to the impact of
meiotic and mitotic nondisjunction events (Verlinsky et al.,
2008). It may, therefore, generally prove very difficult to
obtain abnormal hESC lines for scientific study from aneuploid
PGD embryos, which will limit our ability to study the bio-
logical consequences of chromosomal abnormalities.
Furthermore, the success rates for generating aneuploid
cell lines originating from fertilized oocytes carrying a
prezygotic nondisjunction error seem to mirror the mis-
carriage rates seen for pregnancies resulting from embryos
carrying such errors.Table 1 Comparison of success rates for generating hESC lines b
No. of karyotypically abnormal blastocysts
No. of embryos with ambiguous results
No. of hESC lines
No. of euploid hESC lines from ambiguous results
No. of euploid hESC lines from proven errors
No. of hESC lines from proven monosomies and trisomies
Success rate per blastocyst
No. of hESC lines (%)
No. of hESC lines (%) from proven monosomies and trisomies (PB)
No. of hESC lines (%) from proven errors
% euploid hESC lines from proven errors
Group II vs Group III, P=0.09.
Group II vs Group IV, P=0.22.
Group III vs Group IV, P=0.54.
⁎ Group I vs Group II, Pb0.01; vs Group III, P=0.12; vs Group IV, P
⁎⁎ Group I vs Group II, Pb0.01; vs Group III, Pb0.05; vs Group III, P
⁎⁎⁎ Group I vs Group II, Pb0.01; vs Group III, Pb0.01; vs Group III, PResults
We defined and studied four groups of aneuploidies:
Group I consisted of exclusively PB diagnosis and
blastocysts originating from zygotes that tested positive for
monosomy, trisomy, or multiple errors. Such chromosomal
abnormalities comparably originate from meioses I and II
(Kuliev and Verlinsky, 2004). Usually, all cells in the resulting
embryos are abnormal for the same chromosome(s). In Group
I, 87 blastocysts from a total of 174 karyotypically abnormal
blastocysts were trisomic, 45 were monosomic, and 42
showed multiple abnormalities. Four blastocysts in this
group had an ambiguous result (trisomy 13, trisomy 21,
monosomy 21, and monosomy 22).
Group II consisted of exclusively PB diagnosis and
blastocysts originating from zygotes showing a balanced
karyotype. It is known that approximately 43% of oocytes
with meiosis I errors also have sequential meiosis II errors,
resulting in 33% of cases in karyotypically balanced zygotes.
The cause for the formation of such balanced zygotes is not
yet understood. We suggest that the underlying mechanism is
an “aneuploidy rescue” event in female meiosis. This event
may be similar to the well-known phenomenon of “trisomy
rescue” in postzygotic embryo development, which may
result in uniparental disomy and imprinting disorders (Kuliev
and Verlinsky, 2004). Nonetheless, such embryos either have
a stable diploid karyotype or may show a predisposition to
further postzygotic and, as a result, mitotic nondisjunction
events. Group II contained 37 blastocysts, all carrying a
balanced chromosomal error.
Group III consisted of PB1 and/or PB2 karyotypically
normal and blastomere biopsy showing chromosomal errors.
Such chromosomal abnormalities may arise from mitotic
errors in one or more blastomeres of an otherwise karyoty-
pically normal embryo. These embryos can be classified as
being mosaic, with a mix of karyotypically normal and
abnormal cells. Group III incorporated 99 karyotypically
abnormal blastocysts, of which 35 were diagnosed asetween the four different groups
Group I Group II Group III Group IV
174 37 99 139
4 – – –
7 8 9 17
4 – – –
0 8 8 15
3
7/174 (4.0) ⁎ 8/37 (21.6) 9/99 (9.1) 17/139 (12.2)
3/128 (2.4) ⁎⁎ – – –
2/170 (1.2) ⁎⁎⁎ – – –




80 Y. Verlinsky et al.trisomic, 47 as monosomic, and 17 as having multiple chro-
mosomal abnormalities.
Group IV consisted of embryos that tested positive for
chromosome errors after blastomere diagnosis alone. We
assume that the major sources of chromosomal abnormalities
in embryos are meiosis I and II errors, with mitotic errors
playing a tangential role (Kuliev and Verlinsky, 2004). However,
as data on PBs aremissing in Group IV, we can only speculate on
the underlying cause for the chromosomal abnormalities:
meiotic error with predisposition to further mitotic errors,
aneuploidy rescue of an abnormal zygote during the first
mitotic divisions, or primarily postzygotic mitotic errors of
single cells. In Group IV, 44 of 139 karyotypically abnormal
blastocysts were diagnosed as trisomic, 55 as monosomic, and
40 as carrying multiple errors.
As summarized in Table 1, the overall success rate for
generating karyotypically normal and abnormal stem cell
lines from blastocysts originating from chromosomal abnor-
mal zygotes and embryos differed statistically significantly
between Group I (4.0%), Group II (21.6%), and Group IV
(12.2%). Excluding those blastocysts in Group I originating
from zygotes with ambiguous results, the success rate for
generating hESC lines including only monosomies and
trisomies dropped to 2.4% with 0% chromosomally normal
lines and differed significantly from the other three groups.
One hundred percent of hESC lines derived from 37
chromosomally abnormal blastocysts in Group II had a normal
karyotype at least up to passages 10–15. In Groups III and IV,
where PB diagnosis showed a normal result and blastomere
testing was abnormal (Group III) or where only blastomere
biopsy was performed (Group IV), all but three resulting stem
cell lines were karyotypically normal (89 and 88% overall
success rate in Groups III and IV, respectively, for generating
karyotypically normal hESC lines). Two abnormal hESC lines
had the same sex chromosome abnormality as the tested
embryo, and one presented a different anomaly compared to
the original PGD analysis (47XY+21 in blastomere analysis,
46XY/49XXY+12+15 in the resulting hESC line).Discussion
At least 50% of oocytes have ameiotic I or II error (Verlinsky et
al., 2001; Kuliev et al., 2005). In this study, the success rate of
establishing hESC lines from aneuploid zygotes, including
those with trisomies andmonosomies, was as low as 2.4%. Our
results clearly show that in the process of generating hESC
lines it would be useful to perform testing of both PBs and one
blastomere from day 3 embryos to predict the success rate of
establishing hESC lines from embryos that harbor prezygotic
meiotic errors (Kuliev et al., 2005).
As of now, only crude estimates on pregnancy loss due to
such aneuploidies are available. There are, for example,
estimates based on surveys that calculate maternal age-
specific incidences of trisomy 21 at birth (Hecht and Hook,
1994). In other cases, estimates are based on comparing the
birth prevalence of trisomy 21 (Hecht and Hook, 1994) to its
prevalence in women undergoing second-trimester amnio-
centesis or first-trimester chorionic villus sampling. Rates of
spontaneous fetal death between different gestations and
delivery at 40 weeks were estimated on the basis of both the
observed prevalence in pregnancies that had antenatal fetalkaryotyping and the reported prevalence in live births
(Snijders et al., 1994; Snijders et al., 1995; Snijders et al.,
1999; Halliday et al., 1995). All these studies found that the
prevalence of trisomy 21 is influenced by maternal age and is
higher in early pregnancy than in live births. Furthermore,
the estimated rates of fetal loss show an overall decrease
over the course of pregnancy, with the highest loss rates
estimated to occur before 10 weeks.
Similar methods were used to produce risk estimates for
other chromosomal abnormalities (Snijders et al., 1995). For
example, the rate of intrauterine lethality for trisomies 18 and
13 between 12 and 40 weeks was calculated to be about 80%.
The vast majority (95%) of all observed cases of Down
syndrome result from meiotic nondisjunction events (88%
originating from nondisjunction in the maternal gametes and
8% from nondisjunction in the paternal gametes), 2–3% from
Robertsonian translocation, and 1–2% from mosaicism
(either postzygotic nondisjunction during early embryo cell
division, leading to a fraction of the cells with trisomy 21, or
through postzygotic aneuploidy rescue, by which some of the
cells of the embryo revert to the normal chromosomal set).
Down syndrome is rarely due to a duplication of a portion of
chromosome 21 (Down syndrome occurrence rates (NIH),
retrieved on 12 April 2008: http://www.nichd.nih.gov/
publications/pubs/downsyndrome.cfm#TheOccurrence).
Considering the available estimates of pregnancy loss due
to aneuploidies as outlined above, the true rate of pregnancy
loss with aneuploid embryos resulting from prezygotic
nondisjunctions if extrapolated from our findings could be
as high as 97.6% for both trisomy 21 and trisomy 13, with only
2.4% reaching live birth. Although postzygotic aneuploidy
rescue may occur in embryos aneuploid from the onset, we
observed no karyotypically normal cells in all three aneu-
ploid hESC lines (trisomy 13, trisomy 21, and monosomy 22).
Further follow-up in these abnormal hESC lines may provide
more information on the true incidence of pre- and
postzygotic aneuploidy rescue.
Group IV may represent a mix of embryos, originating from
prezygotic meiotic and postzygotic mitotic errors, with the
overall success rate for establishing hESC lines similar to that
of Group III (9.1%) (P=0.54) and in between Groups I and II. As
all but one of the hESC lines fromGroup III and all but two from
Group IV were karyotypically normal (89 and 88% normal
stem cell lines for Groups III and IV, respectively), either a
postzygotic mitotic aneuploidy rescue occurred or otherwise
normal cells had a survival advantage over chromosomally
unstable cells in the long run (Peura et al., 2008). Our results
show that only a small fraction of embryos with a proven
aneuploidy after PB testing can generate aneuploid hESC lines.
From this it can be deduced that survival chances are very low
for karyotypically abnormal cells in the mosaic embryos in
Groups III and IV, irrespective of the underlying cause for the
mosaicism: meiotic error with predisposition to further
mitotic errors, aneuploidy rescue of an abnormal zygote
during the first mitotic divisions, or primarily postzygotic
mitotic errors of single cells. In most cases, only those cells
with a normal chromosomal makeup probably contributed to
the newly created stem cell lines. However, regarding the two
karyotypically abnormal hESC lines observed in Group IV, it
could well be that selection of the fastest growing colonies
during the derivation phase of the lines may have resulted in
adapted chromosomally abnormal hESC lines.
81PGD for chromosomal aneuploidies and establishment of hESC linesIt is well accepted that the efficiency of hESC production
is influenced by a number of factors, in particular, the quality
of the blastocysts and the degree of lethality of each type of
aneuploidy at different stages of preimplantation develop-
ment. Furthermore, we are aware of the fact that the
original diagnosis of biopsied PBs and/or blastomeres was
performed by FISH and was limited to the analysis of 10 of the
24 chromosomes. It might, therefore, be argued that any
undiagnosed aneuploidies in the remaining 14 chromosomes
could have influenced hESC production, particularly if their
incidence is disproportionate between the four groups of
blastocysts.
As shown earlier by our group (Kuliev et al., 2005), the
errors of the tested chromosomes represent the majority of
chromosomal abnormalities in the embryo, as remaining
untested chromosomes are very rarely involved in meiotic
errors. Additionally, a large proportion of cases represents
complex abnormalities, with an extremely high frequency
of additional errors in meiosis I and meiosis II, as well as
sequential meiosis I and meiosis II errors of the same and
additional chromosomes involved. Furthermore, the previous
data on comparative genomic hybridization (CGH) showed no
significant difference between FISH and CGH data, although
the CGH technique has still not been improved to the extent
that it is sufficiently reliable in single cells and as such cannot
be used for practical purposes.
As for the blastocyst quality, our preliminary data show no
significant differences between blastocysts with normal and
those with abnormal karyotypes, neither in this study nor in
our previous publication on this subject (Verlinsky and Kuliev,
2005).
The data presented suggest the prognostic value of
sequential PB1 and PB2 analysis in addition to blastomere
biopsy on day 3, not only for the preselection of chromoso-
mally normal embryos suitable for transfer, but also for the
highest success rate in establishing hESC lines. Furthermore,
abnormal hESC lines from aneuploid PGD embryos might
prove very difficult to produce, thus limiting our ability to
study the biological consequences of chromosomal
abnormalities.Methods
Preimplantation genetic diagnosis
The preimplantation embryos for the establishment of hESC
lines with genetic disorders were obtained from PGD cycles
that had been performed either by sequential PB1 and PB2
biopsy followed by the removal of one blastomere from day 3
embryos or by single blastomere biopsy alone on day 3, as
described elsewhere (Verlinsky and Kuliev, 2000). Following
both FISH analysis of the biopsied materials using probes
specific for chromosomes 13, 16, 18, 21, and 22, and
rehybridization using specific probes for 9, 15, 17, X, and Y
chromosomes in blastomere analysis, the unaffected
embryos were transferred back to patients. The chromoso-
mally abnormal ones were used for derivation of hESC lines,
according to informed consent as approved by the IRB of the
Reproductive Genetics Institute. Our policy is not to transfer
any embryos in cases in which chromosomal errors cannot
completely be ruled out because of ambiguous results due toa large signal or overlapping signals, loss of nuclear material
during fixation, or poor hybridization.
Categories of aneuploid embryos
Four groups of aneuploidies were studied: Group I, exclu-
sively PB diagnosis and blastocysts originating from zygotes
that tested positive for monosomy, trisomy, or multiple
errors; Group II, exclusively PB diagnosis and blastocysts
originating from zygotes showing a balanced karyotype;
Group III, PB1 and/or PB2 karyotypically normal and
blastomere biopsy showing chromosomal errors; and Group
IV, embryos tested positive for chromosome errors after
blastomere diagnosis alone.
Isolation and characterization of hESC lines
Depending on the developmental stage of these aneuploid
embryos, different techniques for the establishment of hESC
lines were used, as described previously (Strelchenko et al.,
2004). The initial disaggregation of the cells (passage 0) was
performed approximately 8–14 days after growth on the
feeder layer, by treating the cells with EDTA and cutting and
transferring the soft cell clumps into a new dish with the
feeder layer. Fast-proliferating colonies with hESC-like
morphology were isolated and propagated further. Within
the next 2–5 passages, the uniformly proliferating cells were
selected, and colonies of established ESC lines were
passaged using EDTA. This was followed by the harvesting
procedure with a cell lifter, as described previously
(Strelchenko et al., 2004).
The cell lines were tested for the following hESC markers:
alkalinephosphatase, stage-specific antigens SSEA-3 and SSEA-
4, high-molecular-weight glycoproteins or tumor rejection
antigens, TRA-1–60 and TRA-1–80, and Oct-4. Detection was
achieved using both polyclonal antibodies and theGeneChoice
One Tube RT-PCR kit (Vector Laboratories, Burlingame, CA,
USA), as described previously (Strelchenko et al., 2004).
Regular chromosomal analysis was performed using the G-
banding technique on 10–20 cells of the established hESC
lines before freezing at passage 10–15.
Statistical analysis
A double-sided Fisher's exact test was conducted to compare
the different groups, using SPSS for Windows 11.0 (Chicago,
IL, USA). Percentages were rounded up to the first decimal
place. P values below 0.05 were considered to be statistically
significant.
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